Structure Therapeutics (GPCR) Operating Expenses (2022 - 2026)

Structure Therapeutics' Operating Expenses history runs 5 years deep, the most recent figure standing at $89.4 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 58.72% year-over-year to $89.4 million; the TTM figure through Mar 2026 stood at $209.6 million (up 14.85% YoY), while the FY2025 annual figure was $176.6 million, up 11.59% from the prior year.
• Operating Expenses was $89.4 million for Q1 2026 at Structure Therapeutics, up from -$24.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $89.4 million in Q1 2026 to a low of -$24.0 million in Q4 2025.
• Historically, Operating Expenses has averaged $34.1 million across 5 years, with a median of $31.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 139.23% in 2023, then slumped 150.97% in 2025.
• A 5-year view of Operating Expenses shows it stood at $13.0 million in 2022, then surged by 139.23% to $31.0 million in 2023, then surged by 51.84% to $47.1 million in 2024, then sank by 150.97% to -$24.0 million in 2025, then soared by 472.58% to $89.4 million in 2026.
• The last three Operating Expenses figures came in at $89.4 million (Q1 2026), -$24.0 million (Q4 2025), and $73.8 million (Q3 2025), per Business Quant data.